Astellas will pay $100 million while Amgen will pay $24.75 million, the department said. - First-in-Class Antibody-Drug Conjugate Directed Against Nectin-4, a Protein Highly Expressed in Urothelial Tumors1,2 - - PADCEV is the First Treatment Approved for Locally Advanced or Metastatic Urothelial Cancer Following Treatment with Platinum-based Chemotherapy and a PD-1 or PD-L1 Inhibitor - Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas … Find the latest ASTELLAS PHARMA (ALPMY) stock quote, history, news and other vital information to help you with your stock trading and investing. Astellas News Room; Important Notice. Astellas Pharma Inc. agreed to buy Audentes Therapeutics Inc. for about $3 billion, the latest deal by a pharmaceutical company eager to push into promising gene-therapy technologies. Committing for Change: Volunteering More than Just a Day. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. Dive Insight: Since Astellas … Contacts. Fezolinetant, a selective neurokinin-3 (NK3) receptor antagonist, is an investigational oral, non... TOKYO, March 26, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that Smyraf® 50 mg and 100 mg Tablets (generic name: peficitinib hydrobromide), an oral Janus kinase (JAK) inhibitor, received manufacturing and marketing approval in Japan for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in... Notice of Completion of Acquisition of Own Shares, Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients. Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer. This website is intended for U.S. residents only. You are now leaving www.astellas.com/us. Aug 7, 2019 Astellas Announces Collaboration with the Jewish Association Serving the Aging (JASA) to Improve Chronic Disease and Bladder Health Management Astellas seeks external … Astellas participates in Access Accelerated. Oct 18, 2019 To enable deeper stakeholder understanding of Astellas' efforts to continue to create value for sustainable growth, we have published the annual report … 16, 2019- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas… Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Astellas announced today that PROGRAF® Granules (tacrolimus for oral suspension) is now available for prescription in the United States. - Accelerated approval follows priority review designation and inclusion in overseas new drugs urgently needed in clinical settings - -­ XOSPATA® is the first and only FLT3 inhibitor approved by the NMPA for patients with relapsed or refractory AML - TOKYO, February 4, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas… NORTHBROOK, Ill., October 1, 2019 /3BL Media/ -- Astellas Pharma US, Inc. ("Astellas") has announced the finalists for its fourth annual C3 (Changing Cancer Care) Prize, a … Dec 3, 2019. Stories about how Astellas members work to create innovation, as well as achieve business and sustainability strategic goals. The website you are linking to is neither owned nor controlled by Astellas. Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting ; Struggling … Get the latest industry news first when you subscribe to our daily newsletter. This website provides access to information from Astellas sponsored clinical trials and the purpose is not to promote or advertise any... Read More Corporate Responsibility TOKYO, Sept. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the Committee for Medicinal Products for Human … News / Therapeutic Area News Dec 21, 2020 Astellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation … Astellas agrees that the United States, at a minimum, shall be entitled to recoup from Astellas any overpayment plus applicable interest and penalties as a result of the . A high-level overview of Astellas Pharma Inc. (ALPMF) stock. TOKYO and SAN FRANCISCO, Jan. 30, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: … MENLO PARK, Calif., Dec. 5, 2019 /PRNewswire/ -- Astellas Venture Management (President: Shunichiro Matsumoto, Ph.D., MBA, "AVM"), a wholly-owned venture capital subsidiary of Astellas … Feature Stories showcase the people and programs that bring to life the Astellas Way values and culture. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. The Focus Area, where we put our efforts, consists of combinations of three components: 1) biology, 2) modality/technology, 3) diseases. Astellas Pharma has agreed to acquire Audentes Therapeutics for approximately $3 billion cash, in a deal the companies say is intended to create a top-tier gene therapy developer. Enfortumab vedotin to be reviewed by Ministry of Health, Labour and Welfare for patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication TOKYO, March 11, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health... Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives, Astellas Announces Positive Topline Results from Two Phase 3 Pivotal Global Trials of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Postmenopausal Women. Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of … TOKYO, March 11, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug … Astellas monitors Focus Areas from biology perspectives, modality/technology, and disease to identify promising areas for investment.Â. ... 2019 Archives. News; The Astellas Way Blog; Important Notice. Xyphos will become a subsidiary of Astellas, with Knighton and Chairman and Chief Scientific Officer Dave … Unfortunately, we weren't able to find a match for you. BOSTON – The U.S. Attorney’s Office announced today that two pharmaceutical companies – Astellas Pharma US, Inc. (Astellas), and Amgen Inc. (Amgen) – have agreed to pay a … - Submissions will be Reviewed Under Real-Time Oncology Review Based on Clinical Trials EV-301 and Cohort 2 of EV-201 - TOKYO and BOTHELL, Wash. – Feb. 18, 2021 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food... Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV. Review our consolidated business results, forecasts and financial data, etc. TOKYO, February 19, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the Phase 3 pivotal SKYLIGHT 1™ and SKYLIGHT 2™ clinical trials for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) – i.e., hot flashes associated... Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV. Astellas’ sponsorship of the Golden Ticket Competition follows AVM becoming a limited Partner of the venture capital firm Mission Bay Capital in May 2019 and obtaining Gold Sponsorship of … Astellas Pharma U.S. and Amgen agreed to pay $124.75 million to settle charges they violated the False Claims Act by illegally paying the co-pays to induce Medicare patients […] News Local News Mark Niemaszek, Vice President, Commercial Operations, Astellas Pharma US, Inc. Nov 8, 2019… 8 ... Microsoft Word - 2019.04.15 - Astellas … Steady results as projected for the first year of Strategic Plan 2018. PROGRAF is used in combination with other... California Declaration of Comprehensive Compliance Program, Vermont’s Pharmaceutical Marketer Price Disclosure, Wholesale Acquisition Cost Information for Colorado Prescribers, Consumer Product Safety Commission Regulations. Unfortunately, we weren't able to find a match for your search query. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Please try again. Steady results as projected for the first year of Strategic Plan 2018. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Annual Report 2020 is now available at the following link: https://www.astellas.com/en/investors/annual-report In order to provide timely information, we publish the Annual Report on the web site. With another stock surge today, Adaptimmune has gained more than $2 billion in valuation, taking it above the billion-dollar mark for the first time since mid-2019. -Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology- Jul. Pfizer and Astellas' stalwart prostate cancer med Xtandi has watched as Johnson & Johnson's challenger, Erleada, picked up the lead in the metastatic, castration-sensitive form of the … ... Astellas buys Xyphos – and its cell therapy platform – for $665M ... 2019 at 10:52 AM . Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer 09/16/2019 - Food … Sorry, you need to enable JavaScript to visit this website. Astellas Submits New Drug Application for Enfortumab Vedotin in Japan. Neither company admitted wrongdoing. Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201 FAX: +81-3-5201-7473 Audentes Therapeutics, Inc. Investors Contact: Andrew Chang TEL: +1-415-818-1033 Email: … Thank you for visiting the Astellas Pharma Inc. Website. Sorry, you need to enable JavaScript to visit this website. The information in the... Medical Care & Pharmaceutical Information, Rx+® - New Healthcare Solutions Beyond Medicine, Patient Outcome Maximization via Precise Surgery/Diagnosis, Communication with the World Anti-Doping Agency (WADA), Astellas Environment, Health & Safety Guidelines, Biodiversity and Astellas An Enlarged Version, The Biodiversity Burden Index and Revenue, Environmental Impact of Products and Countermeasures, Environment-related Investments and Expenses, Providing Opportunities for Employees to Succeed Globally, ISO certification status of Astellas plants, Basic policy for procurement activities involving suppliers, Research Activities on Tuberculosis and Malaria, Development of Pediatric Formulation for Schistosomiasis, Consolidated Financial Statements and Footnotes. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, … - Findings from the EV-301 Trial Showed Significant Improvements in Overall Survival and Progression-Free Survival Compared to Chemotherapy - - EV-301 Intended to Support Global Registrations, Convert Accelerated to Regular Approval in U.S. - - Data Published in the New England Journal of Medicine, Presented at the 2021 ASCO Genitourinary Cancers Symposium - TOKYO and BOTHELL, Wash. – February 12... Astellas publish its annual report as an integrated report to enable deeper stakeholder understanding of Astellas' efforts to continuously create value for sustainable growth. By using this site, you accept our use of cookies as described in our privacy policy. Please read our privacy policy for more information on the cookies we use, the processing of your personal data and how to delete or block the use of cookies. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. TOKYO, February 19, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the Phase 3 pivotal SKYLIGHT 1™ … Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the first cohort of... Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society’s Annual Meeting (ENDO) - Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women -. TOKYO, March 26, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from a Phase 2b dose-finding study of fezolinetant, presented in an oral session (Abstract OR33-6) at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans.